ORASURE TECHNOLOGIES, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ORASURE TECHNOLOGIES, INC (OSUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.04% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-09
- ORASURE TECHNOLOGIES, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.04%, a 2.42% decline from fiscal 2024.
- ORASURE TECHNOLOGIES, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.14%, a 2.13% decline from fiscal 2023.
- ORASURE TECHNOLOGIES, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.23%, a 156.36% increase from fiscal 2022.
- ORASURE TECHNOLOGIES, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.65%, a 251.06% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2025-12-31 | 4.04% 10-K · filed 2026-03-09 |
| 2024-12-31 | 4.14% 10-K · filed 2026-03-09 |
| 2023-12-31 | 4.23% 10-K · filed 2026-03-09 |
| 2022-12-31 | 1.65% 10-K · filed 2025-03-07 |
| 2021-12-31 | 0.47% 10-K · filed 2024-03-11 |
| 2020-12-31 | 1.33% 10-K · filed 2023-03-03 |
| 2019-12-31 | 2.52% 10-K · filed 2022-03-01 |
| 2018-12-31 | 2.60% 10-K · filed 2021-03-01 |
| 2017-12-31 | 2.22% 10-K · filed 2020-03-02 |
| 2016-12-31 | 1.76% 10-K · filed 2019-02-28 |
| 2015-12-31 | 1.49% 10-K · filed 2018-02-28 |
| 2014-12-31 | 2.13% 10-K · filed 2017-03-14 |
| 2013-12-31 | 1.47% 10-K · filed 2016-03-14 |
| 2012-12-31 | 0.99% 10-K · filed 2015-03-12 |
| 2011-12-31 | 1.36% 10-K · filed 2014-03-14 |
| 2010-12-31 | 1.89% 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |